Unraveling the Role of Molecular Profiling in Predicting Treatment Response in Stage III Colorectal Cancer Patients: Insights from the IDEA International Study.
IDEA study
bioinformatics
colorectal cancer
molecular profiling
stage III
whole exome sequencing
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
30 Sep 2023
30 Sep 2023
Historique:
received:
16
08
2023
revised:
06
09
2023
accepted:
28
09
2023
medline:
14
10
2023
pubmed:
14
10
2023
entrez:
14
10
2023
Statut:
epublish
Résumé
This study aimed to investigate the molecular profiles of 237 stage III CRC patients from the international IDEA study. It also sought to correlate these profiles with Toll-like and vitamin D receptor polymorphisms, clinicopathological and epidemiological characteristics, and patient outcomes. Whole Exome Sequencing and PCR-RFLP on surgical specimens and blood samples, respectively, were performed to identify molecular profiling and the presence of Toll-like and vitamin D polymorphisms. Bioinformatic analysis revealed mutational status. Among the enrolled patients, 63.7% were male, 66.7% had left-sided tumors, and 55.7% received CAPOX as adjuvant chemotherapy. Whole exome sequencing identified 59 mutated genes in 11 different signaling pathways from the Kyoto Encyclopedia of Genes and Genomes (KEGG) CRC panel. On average, patients had 8 mutated genes (range, 2-21 genes). Mutations in Molecular characterization of tumor cells can enhance our understanding of the disease course. Mutations may serve as promising prognostic biomarkers, offering improved treatment options. Confirming these findings will require larger patient cohorts and international collaborations to establish correlations between molecular profiling, clinicopathological and epidemiological characteristics and clinical outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
This study aimed to investigate the molecular profiles of 237 stage III CRC patients from the international IDEA study. It also sought to correlate these profiles with Toll-like and vitamin D receptor polymorphisms, clinicopathological and epidemiological characteristics, and patient outcomes.
METHODS
METHODS
Whole Exome Sequencing and PCR-RFLP on surgical specimens and blood samples, respectively, were performed to identify molecular profiling and the presence of Toll-like and vitamin D polymorphisms. Bioinformatic analysis revealed mutational status.
RESULTS
RESULTS
Among the enrolled patients, 63.7% were male, 66.7% had left-sided tumors, and 55.7% received CAPOX as adjuvant chemotherapy. Whole exome sequencing identified 59 mutated genes in 11 different signaling pathways from the Kyoto Encyclopedia of Genes and Genomes (KEGG) CRC panel. On average, patients had 8 mutated genes (range, 2-21 genes). Mutations in
CONCLUSIONS
CONCLUSIONS
Molecular characterization of tumor cells can enhance our understanding of the disease course. Mutations may serve as promising prognostic biomarkers, offering improved treatment options. Confirming these findings will require larger patient cohorts and international collaborations to establish correlations between molecular profiling, clinicopathological and epidemiological characteristics and clinical outcomes.
Identifiants
pubmed: 37835512
pii: cancers15194819
doi: 10.3390/cancers15194819
pmc: PMC10571744
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Hellenic Society of Medical Oncology
ID : N/A
Organisme : Gastrointestinal cancer study group
ID : N/A
Références
Cancers (Basel). 2022 Sep 10;14(18):
pubmed: 36139567
Lancet Oncol. 2010 Aug;11(8):753-62
pubmed: 20619739
Cell. 2000 Oct 13;103(2):311-20
pubmed: 11057903
Hum Genomics. 2015 Aug 19;9:20
pubmed: 26286629
Nat Cell Biol. 2013 Apr;15(4):338-44
pubmed: 23548926
Inflamm Bowel Dis. 2022 Mar 2;28(3):447-454
pubmed: 34347074
FEBS Lett. 2010 Nov 5;584(21):4463-8
pubmed: 20937277
Nat Nanotechnol. 2009 Apr;4(4):265-70
pubmed: 19350039
Nat Cell Biol. 2002 Jun;4(6):462-7
pubmed: 12032546
J Mol Cell Biol. 2020 Jul 3;12(6):410-423
pubmed: 31065691
Gastroenterology. 2021 Sep;161(3):814-826.e7
pubmed: 33992635
Br J Cancer. 2018 Oct;119(7):785-792
pubmed: 30287914
Front Genet. 2022 Jan 27;12:755629
pubmed: 35154239
Int J Gen Med. 2022 Apr 05;15:3651-3662
pubmed: 35411179
N Engl J Med. 2016 Sep 22;375(12):1109-12
pubmed: 27653561
Oncogene. 2006 Dec 4;25(57):7531-7
pubmed: 17143297
Nature. 2019 Oct;574(7779):532-537
pubmed: 31645730
Nat Med. 2015 Nov;21(11):1350-6
pubmed: 26457759
PLoS One. 2021 Nov 29;16(11):e0259185
pubmed: 34843512
Science. 2013 Mar 29;339(6127):1546-58
pubmed: 23539594
Neoplasia. 2021 May;23(5):488-501
pubmed: 33906087
Aging (Albany NY). 2020 Nov 26;13(1):750-768
pubmed: 33254149
J Am Stat Assoc. 1949 Sep;44(247):335-41
pubmed: 18139350
Onco Targets Ther. 2020 Dec 08;13:12601-12613
pubmed: 33335401
Sci Rep. 2017 Nov 21;7(1):15959
pubmed: 29162841
Cancer Res Treat. 2019 Oct;51(4):1518-1526
pubmed: 30913862
Nat Rev Cancer. 2019 Sep;19(9):495-509
pubmed: 31406302
BMC Cancer. 2021 Mar 16;21(1):282
pubmed: 33726687
Oncotarget. 2017 Nov 7;8(66):110635-110649
pubmed: 29299175
N Engl J Med. 2018 Mar 29;378(13):1177-1188
pubmed: 29590544
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
J Pathol Transl Med. 2020 Sep;54(5):351-360
pubmed: 32580539
Br J Cancer. 2013 May 28;108(10):2153-63
pubmed: 23660947
Br J Cancer. 2001 Sep 1;85(5):692-6
pubmed: 11531254
Cell Mol Biol (Noisy-le-grand). 2022 Feb 04;67(5):356-362
pubmed: 35818232
World J Surg. 2022 Jul;46(7):1734-1755
pubmed: 35325347
Gut. 2022 Jun;71(6):1127-1140
pubmed: 34230216
J Gastrointest Surg. 2020 Jun;24(6):1402-1410
pubmed: 32128676
Cancers (Basel). 2020 Apr 24;12(4):
pubmed: 32344707
Nat Rev Drug Discov. 2014 Jul;13(7):497-512
pubmed: 24981363
Clin Cancer Res. 2020 Jan 15;26(2):332-339
pubmed: 31413009
Hered Cancer Clin Pract. 2009 Dec 23;7(1):17
pubmed: 20028567
J Clin Oncol. 2009 Jul 1;27(19):3109-16
pubmed: 19451431
Mol Cell Biochem. 2021 Sep;476(9):3469-3482
pubmed: 33982211
Cancer Genet. 2021 Nov;258-259:27-36
pubmed: 34315006
Gastroenterol Clin North Am. 2016 Sep;45(3):459-76
pubmed: 27546843
Cancers (Basel). 2020 May 27;12(6):
pubmed: 32471257
Nature. 2012 Jul 18;487(7407):330-7
pubmed: 22810696
BMC Bioinformatics. 2017 Jan 3;18(1):8
pubmed: 28049408
Cancers (Basel). 2021 Apr 22;13(9):
pubmed: 33922197
Front Immunol. 2023 Jun 19;14:1160052
pubmed: 37404825
Clin Colorectal Cancer. 2020 Jun;19(2):123-131
pubmed: 32171644
Front Oncol. 2021 Feb 09;10:550986
pubmed: 33634010
Bioengineered. 2020 Dec;11(1):1027-1033
pubmed: 32951505
Oncogenesis. 2021 Jul 16;10(7):53
pubmed: 34272358
EMBO Mol Med. 2021 Oct 7;13(10):e14123
pubmed: 34409732
JAMA. 2011 Jun 8;305(22):2304-10
pubmed: 21642682
Ann Oncol. 2018 May 1;29(5):1099-1107
pubmed: 29438451
Clin Sci (Lond). 2019 May 30;133(10):1197-1213
pubmed: 31109967
Gastrointest Endosc Clin N Am. 2022 Apr;32(2):177-194
pubmed: 35361330
Nat Rev Clin Oncol. 2011 Feb;8(2):97-106
pubmed: 21151206
Oncologist. 2011;16(4):404-14
pubmed: 21406469
Cold Spring Harb Perspect Med. 2016 Mar 01;6(3):a026104
pubmed: 26931810
World J Clin Oncol. 2021 Nov 24;12(11):1000-1008
pubmed: 34909395
PLoS One. 2018 Jun 8;13(6):e0197327
pubmed: 29883450
J Clin Oncol. 2011 Apr 10;29(11):1465-71
pubmed: 21383294
Mutagenesis. 2020 Jul 11;35(3):207-219
pubmed: 31424514